Lenacapavir is a twice-yearly injection that can prevent HIV infections. New licensing deals with Gilead and Indian manufacturers mean it will be available in 120 low- and middle-income countries at about US$40 a year.
The Gates Foundation will help Hetero with funding and volume guarantees and says it invested more than US$80 million to speed production. Dr. Reddy’s will receive help from the Clinton Health Access Initiative, Unitaid and Wits RHI to supply generics from 2027 at the same price. Campaigners warn some middle-income countries are excluded and that money is also needed for awareness, training and supply.
Difficult words
- drug — A substance used for medical treatment.
- injection — A shot given using a needle.
- countries — Nations or areas with their own governments.
- access — The ability to use or reach something.
- funding — Money provided for a specific purpose.
- healthcare — Services related to health and medical care.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is lenacapavir considered a major step in fighting HIV?
- How do you think funding can improve healthcare services?
- What might happen if middle-income countries are excluded from access?
Related articles
Targeting Glut1 in Neutrophils Reduces Kidney Damage
Researchers using a mouse model of antibody-mediated glomerulonephritis found that neutrophils increase Glut1, a glucose transporter. Disabling Glut1 in neutrophils or using a Glut1 inhibitor reduced inflammation and improved kidney pathology in the model.
AI to stop tobacco targeting young people
At a World Conference in Dublin (23–25 June), experts said artificial intelligence can help stop tobacco companies targeting young people online. They warned social media and new nicotine products draw youth into addiction, and poorer countries carry the heaviest burden.